bpi pharmacy tirzepatide 10mg/ml - 3ml vial Howard's - 🌟 Now Available:

Competitive Position Eli Lilly Market Cap: ~$885-930B 2025 Rev Growth: +40-50% Forward P/E: ~31 Positioning: Market leader, oral GLP-1 coming Novo Nordisk Market Cap: ~$204-215B 2025 Rev Growth: +30% Forward P/E: ~12 Positioning: Struggling with competition, stock down 60% from peak Pfizer Market Cap: ~$160B 2025 Rev Growth: Declining Forward P/E: ~12 Positioning: Lost Metsera bid to competition Key Advantages: Tirzepatide (Mounjaro/Zepbound) consistently outperforms Novo's semaglutide (Ozempic/Wegovy) in head-to-head trials First-mover advantage with oral GLP-1 (orforglipron) Manufacturing scale-up: $12.5B+ invested in new facilities (Virginia, Texas, Puerto Rico) Direct-to-consumer platform (LillyDirect) creating pricing flexibility Valuation & Price Targets Current Price: ~$990 Market Cap: ~$885-930B Valuation Framework 2025 Est

GLP-1 medication prices in Delhi in 2026 range from about 1,290/month for generic semaglutide to 27,500/month for high-dose Mounjaro

These fat-burning shots are often used as part of a medically supervised weight-loss program that includes proper hydration, a healthy diet, and routine exercise

His research led to the popular Myers Cocktail

S.MurthyH

Mendhe S, Badge A, Ugemuge S, Chandi D